ZA200306884B - N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermidiate for the compound and processes for producing the same - Google Patents

N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermidiate for the compound and processes for producing the same Download PDF

Info

Publication number
ZA200306884B
ZA200306884B ZA2003/06884A ZA200306884A ZA200306884B ZA 200306884 B ZA200306884 B ZA 200306884B ZA 2003/06884 A ZA2003/06884 A ZA 2003/06884A ZA 200306884 A ZA200306884 A ZA 200306884A ZA 200306884 B ZA200306884 B ZA 200306884B
Authority
ZA
South Africa
Prior art keywords
methyl
amino
isobutyl
thiazolylsulfonyl
furylsulfonyl
Prior art date
Application number
ZA2003/06884A
Other languages
English (en)
Inventor
Hashimoto Shinsuke
Maruyama Takayuki
Kobayashi Kaoru
Naganawa Atsushi
Nakai Yoshihiko
Saitoh Tetsuji
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of ZA200306884B publication Critical patent/ZA200306884B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
ZA2003/06884A 2001-03-12 2003-09-03 N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermidiate for the compound and processes for producing the same ZA200306884B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001068498 2001-03-12
JP2001281569 2001-09-17
JP2002007760 2002-01-16
PCT/JP2002/002245 WO2002072564A1 (en) 2001-03-12 2002-03-11 N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same

Publications (1)

Publication Number Publication Date
ZA200306884B true ZA200306884B (en) 2005-03-30

Family

ID=27346214

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2003/06884A ZA200306884B (en) 2001-03-12 2003-09-03 N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermidiate for the compound and processes for producing the same

Country Status (24)

Country Link
US (3) US7235667B2 (https=)
EP (2) EP1369419B1 (https=)
JP (3) JP3555620B2 (https=)
KR (1) KR100886854B1 (https=)
CN (1) CN1294126C (https=)
AT (2) ATE522513T1 (https=)
AU (1) AU2002238855B2 (https=)
BR (1) BR0208027A (https=)
CA (1) CA2439604C (https=)
CZ (1) CZ304035B6 (https=)
DE (1) DE60220255T2 (https=)
DK (2) DK1369419T3 (https=)
ES (1) ES2286230T3 (https=)
HU (1) HU230056B1 (https=)
IL (2) IL157701A0 (https=)
MX (1) MXPA03008134A (https=)
NO (1) NO329682B1 (https=)
NZ (1) NZ528120A (https=)
PL (1) PL218750B1 (https=)
PT (2) PT1369419E (https=)
RU (1) RU2299202C2 (https=)
TW (1) TWI317359B (https=)
WO (1) WO2002072564A1 (https=)
ZA (1) ZA200306884B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022549A1 (ja) * 2002-09-09 2004-03-18 Ono Pharmaceutical Co., Ltd. ４−メチル−１，３−チアゾール−２−イルスルホニルハライドの製造方法
ES2308139T3 (es) * 2003-01-29 2008-12-01 Asterand Uk Limited Antagonista de receptos ep4.
GB0317500D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Treatment of bph
EP1642594A1 (en) * 2003-06-27 2006-04-05 Ono Pharmaceutical Co., Ltd. Remedy for urinary tract diseases
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
JPWO2006004115A1 (ja) * 2004-07-05 2008-04-24 中外製薬株式会社 過活動膀胱治療剤
JP2008189549A (ja) * 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
JP2009057282A (ja) * 2005-12-19 2009-03-19 Astellas Pharma Inc カルボン酸誘導体又はその塩
TW200817319A (en) * 2006-08-10 2008-04-16 Astellas Pharma Inc Sulfonamide compound or salt thereof
AU2008215431C1 (en) 2007-02-16 2013-10-17 Ono Pharmaceutical Co., Ltd. Therapeutic agent for urinary excretion disorder
DK2177512T3 (da) * 2007-08-01 2012-06-18 Taisho Pharmaceutical Co Ltd S1P1-bindingshæmmer
JP2010043063A (ja) * 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
JP5304785B2 (ja) * 2008-06-23 2013-10-02 アステラス製薬株式会社 スルホンアミド化合物又はその塩
TW201107309A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
CN103209960A (zh) * 2010-07-26 2013-07-17 百时美施贵宝公司 用作cyp17抑制剂的磺酰胺化合物
JP5363636B2 (ja) * 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
US20140039004A1 (en) * 2012-07-31 2014-02-06 Ono Pharmaceutical Co., Ltd. Method of treating of gastroesophageal reflux disease
PL3138633T3 (pl) * 2014-04-30 2019-05-31 Ind Penalver Sl Programowalna głowica koncentryczna do nakładania płynu na pokrywy o różnych kształtach
ES2821962T3 (es) * 2015-11-13 2021-04-28 Dae Woong Pharma Bloqueador de canales de sodio
RU2659955C1 (ru) * 2017-10-26 2018-07-04 Галина Ильхамовна Лукина Способ диагностики высоких гастроэзофагеальных рефлюксов

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2419923A1 (de) * 1973-04-28 1974-11-28 Fujisawa Pharmaceutical Co Sulfonsaeureester, verfahren zu deren herstellung und verwendung derselben als kondensationsmittel
JPS5748534B2 (https=) 1974-03-04 1982-10-16
DE2555048A1 (de) * 1975-12-06 1977-06-30 Pfersee Chem Fab Verfahren und vorrichtung zur herstellung bestaendiger, waessriger emulsionen wasserunloeslicher substanzen
JPS5293469A (en) 1976-02-02 1977-08-05 Fuji Photo Film Co Ltd Method of curing gelatin
JPH05293469A (ja) 1992-04-17 1993-11-09 Toda Constr Co Ltd 滅菌精製水の製造方法およびその装置
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
AU4431400A (en) * 1999-05-12 2000-12-05 Japan As Represented By President Of National Cancer Center Anticancer agents containing ep1 antagonists as the active ingredient
AU6180600A (en) 1999-07-29 2001-02-19 Ono Pharmaceutical Co. Ltd. Sulfonamide derivatives and remedies for allodynia
WO2002072145A1 (en) * 2001-03-14 2002-09-19 Ono Pharmaceutical Co., Ltd. Remedies for depression containing ep1 antagonist as the active ingredient

Also Published As

Publication number Publication date
HUP0400155A2 (hu) 2004-08-30
US7629369B2 (en) 2009-12-08
JPWO2002072564A1 (ja) 2004-07-02
MXPA03008134A (es) 2004-03-10
EP1369419A1 (en) 2003-12-10
JP3741120B2 (ja) 2006-02-01
EP1612208A2 (en) 2006-01-04
PT1612208E (pt) 2011-10-12
US20050124672A1 (en) 2005-06-09
CN1294126C (zh) 2007-01-10
CA2439604C (en) 2012-05-01
NO20034007D0 (no) 2003-09-10
HU230056B1 (hu) 2015-06-29
PL218750B1 (pl) 2015-01-30
JP2004149545A (ja) 2004-05-27
CN1509278A (zh) 2004-06-30
CZ20032452A3 (cs) 2003-11-12
US20060030713A1 (en) 2006-02-09
BR0208027A (pt) 2004-12-28
RU2299202C2 (ru) 2007-05-20
WO2002072564A1 (en) 2002-09-19
DE60220255D1 (de) 2007-07-05
PT1369419E (pt) 2007-08-16
JP3555620B2 (ja) 2004-08-18
IL157701A (en) 2010-06-30
ATE522513T1 (de) 2011-09-15
EP1612208B1 (en) 2011-08-31
NZ528120A (en) 2006-05-26
AU2002238855B2 (en) 2007-12-06
DK1369419T3 (da) 2007-09-24
ATE362924T1 (de) 2007-06-15
CA2439604A1 (en) 2002-09-19
HUP0400155A3 (en) 2007-05-02
JP2006028193A (ja) 2006-02-02
KR100886854B1 (ko) 2009-03-05
EP1612208A3 (en) 2006-12-06
ES2286230T3 (es) 2007-12-01
PL365100A1 (en) 2004-12-27
IL157701A0 (en) 2004-03-28
KR20030082978A (ko) 2003-10-23
TWI317359B (en) 2009-11-21
US8088802B2 (en) 2012-01-03
NO329682B1 (no) 2010-11-29
RU2003127677A (ru) 2005-03-27
US20100041708A1 (en) 2010-02-18
JP4432051B2 (ja) 2010-03-17
US7235667B2 (en) 2007-06-26
CZ304035B6 (cs) 2013-08-28
EP1369419B1 (en) 2007-05-23
DE60220255T2 (de) 2008-01-17
NO20034007L (no) 2003-11-12
DK1612208T3 (da) 2011-12-12
EP1369419A4 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
ZA200306884B (en) N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermidiate for the compound and processes for producing the same
US9387202B2 (en) Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
TWI424999B (zh) 適合作為傑納斯激酶（ｊａｎｕｓ ｋｉｎａｓｅ）抑制劑之氮雜吲哚
JP6942380B2 (ja) 新規イソインドリン誘導体、その医薬組成物および使用
JP7025781B2 (ja) ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法
KR20140021509A (ko) Ｃ－ｍｅｔ 키나아제 억제제 화합물
KR20150085053A (ko) 헤테로사이클릭 글루타미나아제 억제제
JP2000514061A (ja) フィブリノーゲン受容体拮抗物質
KR20120107493A (ko) 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온염
MX2011010065A (es) Novedoso derivado de hidroxamato, un metodo de produccion del mismo y una composicion farmaceutica que comprende el mismo.
CN103079567A (zh) 用于疾病和病症的治疗和预防的氟取代的ω-羧基芳基二苯脲的合成代谢产物
US20040127533A1 (en) Sulfonamide derivatives
JP2011522854A (ja) イミダゾリジン誘導体
JP5243596B2 (ja) Ｈｄｌ−コレステロール上昇剤としての３−トリフルオロメチル−ピラジン−２−カルボン酸アミド誘導体
TW201623226A (zh) 化合物
CA2677769C (en) Therapeutic agent for urinary excretion disorder
JP5442711B2 (ja) Ｈｄｌ−コレステロール上昇剤としての２−トリフルオロメチルニコチンアミド誘導体
WO2006071035A1 (en) Novel ([1,3]thiazolo[5,4-b]pyridin-2-yl)-2-carboxamide derivatives
JP7788532B2 (ja) Ｒｘｆｐ１受容体アゴニスト
US20250361243A1 (en) Compounds and Pharmaceutical Compositions Useful for Managing Sickle Cell Disease and Conditions Related Thereto
JP2008106017A (ja) Ｏａｔｐ選択的阻害性を有する化合物、及び該化合物を含むｏａｔｐの選択的阻害剤
TW201217376A (en) Use for myocardial infarction of KMUP-3